Amanpreet Buttar, MD
Hematology/Oncology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 21
- 5 carriers
- Office
- 1
Offices
1 location · County of Santa Clara · 1,000 clinicians in this group
Looking this up.
Hospitals listed: Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
21 plans · 5 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Buttar’s office at (408) 885-5000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
21 of 21 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A116791 · Current
Licensed to practise in California · since 2011 · expires 2028-07-31 · Baba Farid University of Health Sciences Christian Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$32,950
Medicare paid this office $32,950 for 303 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 108 | $11,939 | $82 |
| Short return visit (20+ min) | 120 | $7,786 | $53 |
| New patient visit (45+ min) | 34 | $3,681 | $108 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 26 | $2,275 | $73 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 13 | $1,505 | $44 |
See all 8 services
| Return visit (30+ min) | 108 | $11,939 | $82 |
| Short return visit (20+ min) | 120 | $7,786 | $53 |
| New patient visit (45+ min) | 34 | $3,681 | $108 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 26 | $2,275 | $73 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 13 | $1,505 | $44 |
| New patient visit (30+ min) | 17 | $1,137 | $67 |
| Telephone medical discussion with physician, 11-20 minutes | 32 | $1,011 | $30 |
| Telephone medical discussion with physician, 5-10 minutes | 29 | $822 | $25 |
Who their Medicare patients are
303 Original Medicare patients in 2024. Average age 73 · Under 65 13% · 85 and older 11% · Women 52% · Also on Medicaid 81% · Health risk score 2.09. Above the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 75% · Diabetes 47% · Cancer 38% · Chronic kidney disease 31% · Heart failure 20% · Coronary heart disease 17% · Atrial fibrillation 16% · Depression 15% · COPD 13% · Stroke 8% · Dementia 7%.
The office billed $311,156, Medicare allowed $46,717 and paid $32,950; for 508 services of 15 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 303 | 508 | 73 | 2.09 | $311,156 | $32,950 |
| 2023 | 225 | 431 | 72 | 2.04 | $216,263 | $26,839 |
| 2022 | 310 | 604 | 71 | 1.82 | $222,632 | $31,175 |
| 2021 | 346 | 691 | 71 | 2.21 | $238,137 | $43,159 |
| 2020 | 271 | 525 | 70 | 2.18 | $183,936 | $23,099 |
| 2019 | 308 | 580 | 70 | 1.89 | $314,087 | $34,607 |
| 2017 | 58 | 75 | 69 | 2.78 | $29,083 | $2,253 |
| 2016 | 199 | 403 | 70 | 1.84 | $121,277 | $19,202 |
| 2015 | 110 | 273 | 69 | 2.28 | $69,721 | $14,475 |
| 2014 | 105 | 236 | 67 | 1.78 | $61,961 | $14,209 |
| 2013 | 76 | 22,645 | 73 | 1.69 | $583,898 | $102,648 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Telephone medical discussion with physician, 11-20 minutes | 94 | $8,243 | $53 |
| Return visit (30+ min) | 73 | $6,647 | $73 |
| Short return visit (20+ min) | 48 | $3,180 | $54 |
| New patient visit (45+ min) | 13 | $1,533 | $118 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,506 | $116 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 14 | $1,050 | $46 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 13 | $1,021 | $79 |
| Telephone medical discussion with physician, 5-10 minutes | 19 | $617 | $27 |
| Short return visit | 12 | $261 | $22 |
2022: 9 services
| Telephone medical discussion with physician, 11-20 minutes | 122 | $8,513 | $49 |
| Return visit (30+ min) | 56 | $5,297 | $87 |
| Telephone medical discussion with physician, 21-30 minutes | 64 | $4,668 | $66 |
| Telephone medical discussion with physician, 5-10 minutes | 99 | $3,942 | $25 |
| Short return visit (20+ min) | 52 | $2,676 | $49 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 19 | $2,191 | $110 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,944 | $72 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 11 | $773 | $39 |
| Short return visit | 11 | $364 | $33 |
2021: 7 services
| Telephone medical discussion with physician, 11-20 minutes | 174 | $16,787 | $59 |
| Telephone medical discussion with physician, 21-30 minutes | 132 | $13,864 | $84 |
| Telephone medical discussion with physician, 5-10 minutes | 75 | $3,303 | $32 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 24 | $2,740 | $110 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 14 | $2,017 | $41 |
| Return visit (30+ min) | 13 | $1,443 | $90 |
| Short return visit (20+ min) | 25 | $1,417 | $57 |
2020: 6 services
| Telephone medical discussion with physician, 11-20 minutes | 149 | $10,523 | $44 |
| Telephone medical discussion with physician, 21-30 minutes | 40 | $3,177 | $71 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 23 | $2,651 | $102 |
| Return visit (30+ min) | 58 | $2,402 | $37 |
| Telephone medical discussion with physician, 5-10 minutes | 67 | $1,743 | $22 |
| Short return visit (20+ min) | 42 | $1,160 | $26 |
2019: 4 services
| Return visit (30+ min) | 165 | $17,638 | $71 |
| Short return visit (20+ min) | 152 | $10,196 | $45 |
| New patient visit (30+ min) | 26 | $1,790 | $69 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 14 | $1,277 | $91 |
2017: 2 services
| Short return visit (20+ min) | 36 | $1,011 | $26 |
| Return visit (30+ min) | 14 | $569 | $38 |
2016: 5 services
| Short return visit (20+ min) | 104 | $6,904 | $39 |
| Return visit (30+ min) | 75 | $6,254 | $64 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 35 | $3,124 | $87 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 21 | $1,822 | $34 |
| Short return visit | 27 | $515 | $17 |
2015: 4 services
| Return visit (30+ min) | 47 | $4,500 | $58 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $3,501 | $61 |
| Short return visit (20+ min) | 57 | $2,587 | $39 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 19 | $1,820 | $87 |
2014: 5 services
| Return visit (30+ min) | 35 | $4,435 | $65 |
| Short return visit (20+ min) | 54 | $2,614 | $38 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $2,242 | $64 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 18 | $1,785 | $89 |
| New patient visit (45+ min) | 12 | $994 | $83 |
2013: 12 services
| Administration of chemotherapy into vein, 1 hour or less | 11 | $5,143 | $139 |
| Short return visit (20+ min) | 37 | $4,523 | $62 |
| Return visit (30+ min) | 15 | $3,013 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $2,384 | $170 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 37 | $1,791 | $11 |
| New patient visit (45+ min) | 13 | $1,463 | $113 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,315 | $60 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 18 | $1,304 | $33 |
| Blood test, comprehensive group of blood chemicals | 21 | $545 | $9 |
| Insertion of needle into vein for collection of blood sample | 34 | $411 | $3 |
| Lactate dehydrogenase (enzyme) level | 17 | $253 | $4 |
| Uric acid level, blood | 11 | $130 | $3 |
Medicaid work
$15,256 in 2024
Medicaid paid $15,256 for 2,205 billed services this clinician did in 2024, up to 86 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 485 | $7,251 |
| Short return visit (20+ min) | 490 | $5,136 |
| New patient visit (45+ min) | 104 | $2,868 |
| Pain severity quantified; pain present (COA) (ONC) | 19 | $0 |
| Pain severity quantified; no pain present (COA) (ONC) | 22 | $0 |
| Medication list documented in medical record (COA) | 532 | $0 |
| Review of all medications by a prescribing practitioner or clinical pharmacist (such as, prescriptions, OTCs, herbal therapies and supplements) documented in the medical record (COA) | 31 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 176 | $0 |
| Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD) | 30 | $0 |
| Most recent systolic blood pressure greater than or equal to 140 mm Hg (HTN, CKD, CAD) (DM) | 34 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 256 | $0 |
| Most recent diastolic blood pressure 80-89 mm Hg (HTN, CKD, CAD) (DM) | 26 | $0 |
| 2024 | 2,205 | 12 | 86 | $15,256 |
| 2023 | 961 | 6 | 78 | $5,545 |
| 2022 | 1,114 | 4 | 85 | $9,886 |
| 2021 | 1,011 | 6 | 63 | $9,147 |
| 2020 | 745 | 7 | 85 | $6,806 |
| 2019 | 2,086 | 9 | 80 | $12,796 |
| 2018 | 2,529 | 11 | 84 | $21,216 |
See the largest Medicaid services in earlier years
2023
| Short return visit (20+ min) | 594 | $2,869 |
| Return visit (30+ min) | 264 | $2,142 |
| New patient visit (45+ min) | 25 | $534 |
| Most recent hemoglobin A1c (HbA1c) level less than 7.0% (DM) | 53 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 12 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 13 | $0 |
2022
| Return visit (30+ min) | 423 | $5,205 |
| Short return visit (20+ min) | 641 | $4,483 |
| Short return visit | 33 | $110 |
| Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | 17 | $87 |
2021
| Short return visit (20+ min) | 578 | $5,351 |
| Return visit (30+ min) | 233 | $2,330 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 90 | $692 |
| Short return visit | 68 | $656 |
| IP/OBS CONSLTJ NEW/EST SF 35 | 15 | $93 |
| SBSQ HOSPITAL IP/OBS CARE SF/LOW MDM 25 MINUTES | 27 | $25 |
2020
| Return visit (30+ min) | 180 | $2,282 |
| Short return visit (20+ min) | 297 | $2,031 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 167 | $1,463 |
| Service | 21 | $716 |
| IP/OBS CONSLTJ NEW/EST SF 35 | 14 | $162 |
| Creatinine; blood | 50 | $87 |
| HEPATIC FUNCTION PANEL | 16 | $65 |
2019
| Return visit (30+ min) | 642 | $3,974 |
| Service | 93 | $3,171 |
| Short return visit (20+ min) | 666 | $2,868 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 176 | $1,552 |
| ELECTROLYTE PANEL | 87 | $680 |
| HEPATIC FUNCTION PANEL | 131 | $304 |
| Blood glucose (sugar) level | 121 | $221 |
| Creatinine; blood | 87 | $24 |
| Urea nitrogen; quantitative | 83 | $1 |
2018
| Service | 253 | $8,606 |
| Return visit (30+ min) | 667 | $5,480 |
| Short return visit (20+ min) | 440 | $2,569 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 271 | $2,328 |
| ELECTROLYTE PANEL | 155 | $1,208 |
| HEPATIC FUNCTION PANEL | 201 | $454 |
| Blood glucose (sugar) level | 188 | $331 |
| Creatinine; blood | 162 | $85 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 13 | $71 |
| Blood count; blood smear, microscopic examination with manual differential WBC count | 17 | $66 |
| Urea nitrogen; quantitative | 162 | $19 |
Drugs they prescribed that Part D paid
$1,482,696
Pharmacies billed $1,482,696 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (12 of 517) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.
414 generic and 103 brand-name prescriptions · $1,482,696 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Tagrisso | 34 | $533,095 | $15,679 |
| Piqray | 14 | $290,088 | $20,721 |
| Abiraterone Acetate | 43 | $70,057 | $1,629 |
| Tenofovir Disoproxil | 12 | $1,789 | $149 |
| Ondansetron | 33 | $872 | $26 |
See all 13 drugs
| Tagrisso | 34 | $533,095 | $15,679 |
| Piqray | 14 | $290,088 | $20,721 |
| Abiraterone Acetate | 43 | $70,057 | $1,629 |
| Tenofovir Disoproxil | 12 | $1,789 | $149 |
| Ondansetron | 33 | $872 | $26 |
| Imatinib Mesylate | 12 | $787 | $66 |
| Anastrozole | 46 | $641 | $14 |
| Loperamide | 24 | $432 | $18 |
| Prochlorperazine Maleate | 35 | $402 | $11 |
| Dexamethasone | 18 | $209 | $12 |
| Acyclovir | 15 | $209 | $14 |
| Prednisone | 48 | $174 | $4 |
| Gabapentin | 13 | $73 | $6 |
Year by year
| 2024 | 517 | 88 | 2% (12) | 20% | $1,482,696 |
| 2023 | 651 | 81 | None | None | $1,935,117 |
| 2022 | 532 | 81 | None | 23% | $1,578,214 |
| 2021 | 447 | 77 | 6% (28) | 24% | $1,202,134 |
| 2020 | 503 | 79 | 5% (23) | 24% | $1,386,203 |
| 2019 | 413 | 79 | 5% (21) | 22% | $944,867 |
| 2018 | 522 | 83 | 5% (24) | None | $998,111 |
| 2017 | 369 | 62 | 5% (19) | None | $517,296 |
| 2016 | 258 | 48 | 7% (19) | None | $320,884 |
| 2015 | 164 | 31 | 9% (15) | 38% | $189,453 |
| 2014 | 91 | 21 | 0% (0) | 45% | $85,252 |
| 2013 | 111 | 30 | 16% (18) | 28% | $66,302 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 18 drugs
| Ibrance | 34 | $539,192 | $15,859 |
| Tagrisso | 29 | $508,808 | $17,545 |
| Abiraterone Acetate | 33 | $217,750 | $6,598 |
| Aprepitant | 15 | $10,927 | $728 |
| Eliquis | 15 | $9,833 | $656 |
| Anastrozole | 43 | $2,041 | $47 |
| Imatinib Mesylate | 18 | $1,440 | $80 |
| Hydroxyurea | 28 | $829 | $30 |
| Loperamide | 27 | $694 | $26 |
| Prochlorperazine Maleate | 45 | $571 | $13 |
| Ondansetron | 51 | $564 | $11 |
| Acyclovir | 15 | $441 | $29 |
| Prednisone | 50 | $418 | $8 |
| Dexamethasone | 27 | $302 | $11 |
| Omeprazole | 12 | $221 | $18 |
| Gabapentin | 15 | $127 | $8 |
| Potassium Chloride | 18 | $109 | $6 |
| Nystatin | 14 | $78 | $6 |
2022: 16 drugs
| Ibrance | 24 | $369,501 | $15,396 |
| Iclusig | 11 | $228,830 | $20,803 |
| Abiraterone Acetate | 21 | $152,533 | $7,263 |
| Sunitinib Malate | 18 | $84,136 | $4,674 |
| Aprepitant | 18 | $10,750 | $597 |
| Imatinib Mesylate | 25 | $2,891 | $116 |
| Hydroxyurea | 35 | $1,089 | $31 |
| Anastrozole | 30 | $968 | $32 |
| Acyclovir | 21 | $463 | $22 |
| Omeprazole | 26 | $362 | $14 |
| Loperamide | 16 | $318 | $20 |
| Prednisone | 41 | $304 | $7 |
| Prochlorperazine Maleate | 17 | $277 | $16 |
| Ondansetron | 27 | $146 | $5 |
| Dexamethasone | 12 | $146 | $12 |
| Potassium Chloride | 16 | $113 | $7 |
2021: 18 drugs
| Ibrance | 28 | $403,953 | $14,427 |
| Pomalyst | 11 | $218,660 | $19,878 |
| Xarelto | 15 | $10,325 | $688 |
| Erlotinib | 11 | $9,902 | $900 |
| Imatinib Mesylate | 14 | $1,614 | $115 |
| Anastrozole | 26 | $754 | $29 |
| Hydroxyurea | 30 | $520 | $17 |
| Acyclovir | 22 | $494 | $22 |
| Dexamethasone | 30 | $411 | $14 |
| Sucralfate | 11 | $400 | $36 |
| Hydrocodone-Acetaminophen | 21 | $327 | $16 |
| Prochlorperazine Maleate | 20 | $304 | $15 |
| Ondansetron | 21 | $212 | $10 |
| Omeprazole | 11 | $207 | $19 |
| Loperamide | 11 | $179 | $16 |
| Amlodipine Besylate | 11 | $127 | $12 |
| Potassium Chloride | 19 | $100 | $5 |
| Gabapentin | 13 | $88 | $7 |
2020: 18 drugs
| Pomalyst | 21 | $414,521 | $19,739 |
| Revlimid | 12 | $190,606 | $15,884 |
| Ibrance | 11 | $142,301 | $12,936 |
| Erlotinib | 14 | $66,734 | $4,767 |
| Xarelto | 12 | $7,073 | $589 |
| Aprepitant | 12 | $6,090 | $508 |
| Imatinib Mesylate | 13 | $4,218 | $324 |
| Prochlorperazine Maleate | 48 | $775 | $16 |
| Anastrozole | 36 | $756 | $21 |
| Hydroxyurea | 31 | $617 | $20 |
| Dexamethasone | 22 | $426 | $19 |
| Ondansetron | 49 | $373 | $8 |
| Letrozole | 13 | $339 | $26 |
| Hydrocodone-Acetaminophen | 23 | $335 | $15 |
| Loperamide | 12 | $203 | $17 |
| Acyclovir | 12 | $145 | $12 |
| Potassium Chloride | 22 | $121 | $6 |
| Omeprazole | 13 | $109 | $8 |
2019: 14 drugs
| Revlimid | 31 | $486,014 | $15,678 |
| Sutent | 11 | $83,309 | $7,574 |
| Jadenu | 11 | $56,324 | $5,120 |
| Aprepitant | 13 | $5,643 | $434 |
| Anastrozole | 41 | $1,134 | $28 |
| Hydroxyurea | 33 | $815 | $25 |
| Acyclovir | 20 | $402 | $20 |
| Ondansetron | 38 | $320 | $8 |
| Prochlorperazine Maleate | 22 | $296 | $13 |
| Hydrocodone-Acetaminophen | 13 | $237 | $18 |
| Dexamethasone | 12 | $219 | $18 |
| Letrozole | 14 | $219 | $16 |
| Omeprazole | 16 | $159 | $10 |
| Prednisone | 12 | $77 | $6 |
2018: 17 drugs
| Revlimid | 31 | $443,298 | $14,300 |
| Tarceva | 14 | $124,960 | $8,926 |
| Aprepitant | 17 | $9,236 | $543 |
| Anastrozole | 36 | $736 | $20 |
| Hydroxyurea | 28 | $630 | $23 |
| Ondansetron | 42 | $401 | $10 |
| Granisetron | 25 | $343 | $14 |
| Prochlorperazine Maleate | 38 | $254 | $7 |
| Dexamethasone | 29 | $210 | $7 |
| Sucralfate | 11 | $189 | $17 |
| Acyclovir | 18 | $189 | $11 |
| Hydrocodone-Acetaminophen | 11 | $152 | $14 |
| Letrozole | 13 | $136 | $10 |
| Potassium Chloride | 14 | $98 | $7 |
| Prednisone | 17 | $84 | $5 |
| Omeprazole | 11 | $65 | $6 |
| Gabapentin | 11 | $61 | $6 |
2017: 10 drugs
| Tarceva | 11 | $84,280 | $7,662 |
| Viread | 16 | $20,817 | $1,301 |
| Hydroxyurea | 40 | $941 | $24 |
| Anastrozole | 31 | $632 | $20 |
| Ondansetron | 28 | $263 | $9 |
| Acyclovir | 19 | $211 | $11 |
| Prochlorperazine Maleate | 20 | $129 | $6 |
| Dexamethasone | 19 | $91 | $5 |
| Prednisone | 13 | $62 | $5 |
| Omeprazole | 11 | $56 | $5 |
2016: 8 drugs
| Revlimid | 11 | $91,050 | $8,277 |
| Procrit | 26 | $86,590 | $3,330 |
| Enoxaparin | 20 | $4,193 | $210 |
| Hydroxyurea | 22 | $337 | $15 |
| Anastrozole | 15 | $229 | $15 |
| Ondansetron | 15 | $168 | $11 |
| Acyclovir | 17 | $168 | $10 |
| Prochlorperazine Maleate | 16 | $117 | $7 |
2015: 3 drugs
| Procrit | 12 | $23,753 | $1,979 |
| Potassium Chloride | 12 | $528 | $44 |
| Acyclovir | 12 | $122 | $10 |
2013: 1 drug
| Xarelto | 12 | $3,268 | $272 |
Money from drug and device companies
$246 in 2025
| 2025 | 1 | 2 | None | $246 |
| 2022 | 1 | 3 | None | $40 |
| 2021 | 1 | 4 | None | $52 |
| 2019 | 2 | 2 | None | $24 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Lynparza | $246 | 2 payments
|
See all 2 published payments
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-04 | Lynparza | $121 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-17 | Lynparza | $125 |
See earlier years (2022, 2021, 2019)
2022: $40
| Acrotech Biopharma | Beleodaq | $40 | 3 payments
|
2021: $52
| Acrotech Biopharma | Beleodaq | $52 | 4 payments
|
2019: $24
| Seattle Genetics | Adcetris | $12 | 1 payment
|
| Pfizer | Ibrance | $12 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 80.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1962679753
- Licence
- CA A116791California A116791: Current · expires 2028-07-31
- Trained
- College of Medicine and Surgery, 2002
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 6380 Clark Ave, Dublin, CA, 94568
- NPI first listed
- 2008-05-12
- NPI last updated
- 2013-04-18
This is when the NPI record was last certified, not a medical board exam.